Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668031 · ClinicalTrials.gov registry record · Phase 3
Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 359
- Enrollment target
NCT00668031 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 359 participants.
The verdict
NCT00668031, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 359 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery. Patients undergoing major surgery are at risk for significant blood loss. Because of this, there is a need for drugs that will help slow the amount of bleeding during surgery.
Interventions
- DRUG Placebo
- DRUG Trasylol (Aprotinin, BAYA0128)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668031
The ClinicalTrials.gov registry entry for NCT00668031 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00668031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668031 about?
NCT00668031 is a clinical study titled "Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement". The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery. Patients undergoing major surgery are at risk for significant blood loss. Becau...
What is the current status of trial NCT00668031?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 359 participants. The study started on 2005-02. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00668031?
The interventions under investigation include: Placebo (DRUG), Trasylol (Aprotinin, BAYA0128) (DRUG).
Who is sponsoring clinical trial NCT00668031?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.